Controlled Attenuation Parameter (CAP) in Liver Allografts

Completed

Conditions studied: Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction

In brief

The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.

Key facts

Study ID

NCT02798861

Run by

Andres Duarte-Rojo

People needed

160

Starts

2016-09-07

Expected to finish

2019-06-01

Last updated by the study team

2020-07-31

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Stanford University — Stanford, California, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.